Authors:
Opal, SM
Sypek, JP
Keith, JC
Schaub, RG
Palardy, JE
Parejo, NA
Citation: Sm. Opal et al., Evaluation of the safety of recombinant P-selectin glycoprotein ligand-immunoglobulin G fusion protein in experimental models of localized and systemic infection, SHOCK, 15(4), 2001, pp. 285-290
Authors:
Murray, HW
Montelibano, C
Peterson, R
Sypek, JP
Citation: Hw. Murray et al., Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis., J INFEC DIS, 182(5), 2000, pp. 1497-1502
Authors:
Kenney, RT
Sacks, DL
Sypek, JP
Vilela, L
Gam, AA
Evans-Davis, K
Citation: Rt. Kenney et al., Protective immunity using recombinant human IL-12 and alum as adjuvants ina primate model of cutaneous leishmaniasis, J IMMUNOL, 163(8), 1999, pp. 4481-4488
Authors:
Thibodeaux, DK
Hunter, SE
Waldburger, KE
Bliss, JL
Trepicchio, WL
Sypek, JP
Dunussi-Joannopoulos, K
Goldman, SJ
Leonard, JP
Citation: Dk. Thibodeaux et al., Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-gamma secretion and not restricted to T and NK cells, J IMMUNOL, 163(10), 1999, pp. 5257-5264
Authors:
Schopf, LR
Bliss, JL
Lavigne, LM
Chung, CL
Wolf, SF
Sypek, JP
Citation: Lr. Schopf et al., Interleukin-12 is capable of generating an antigen-specific Th1-type response in the presence of an ongoing infection-driven Th2-type response, INFEC IMMUN, 67(5), 1999, pp. 2166-2171
Authors:
Kropf, P
Schopf, LR
Chung, CL
Xu, DM
Liew, FY
Sypek, JP
Muller, I
Citation: P. Kropf et al., Expression of Th2 cytokines and the stable Th2 marker ST2L in the absence of IL-4 during Leishmania major infection, EUR J IMMUN, 29(11), 1999, pp. 3621-3628